

## Cardio3 BioSciences Strengthens IP Portfolio with New US Patent

**Mont-Saint-Guibert, Belgium,** - Cardio3 BioSciences (C3BS) (*NYSE Euronext Brussels and Paris: CARD*), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces today that it has strengthened its IP portfolio following the United States Patent and Trademark Office (“USPTO”) issuing of a Notice of Allowance for patent application number US 12/994,626.

The patent’s inventors are Dr Andre Terzic and Dr Atta Behfar, both of the Mayo Clinic (Rochester, US). Cardio3 BioSciences holds an exclusive worldwide licence to the patent under the terms of its long term agreement with the Mayo Clinic concerning the Cardiopoiesis platform.

The patent application covers compositions and methods for obtaining cells to treat heart tissue and specific parts of the Cardiopoiesis process by which Cardio3 BioSciences re-programs stem cells into cardiac progenitor cells during manufacturing.

**Dr Christian Homsy, CEO of Cardio3 BioSciences, said:** “This new patent grant further strengthens our IP around the Cardiopoiesis platform as it covers methods by which C-Cure® (C3BS-CQR-1) is manufactured and the cells obtained by that process. We are very pleased to add this additional layer of protection to our proprietary technology and to benefit again from our highly productive and long-standing agreement with the Mayo Clinic.”

\*\*\* END \*\*\*

For more information contact:

**Cardio3 BioSciences**

Dr Christian Homsy, CEO

Anne Portzenheim, Communication Manager

[www.c3bs.com](http://www.c3bs.com)

Tel : +32 10 39 41 00

[aportzenheim@c3bs.com](mailto:aportzenheim@c3bs.com)

**Citigate Dewe Rogerson**

Chris Gardner

Tel : +44 (0) 207 638 9571

### About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure<sup>®</sup> is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure<sup>®</sup> consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle cells that behave identically to those lost to heart disease. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath<sup>® e2</sup>, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris under the ticker symbol CARD.

*C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. As a result, of these factors investors and prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or review any forward-looking statement, whether as a result of new information, future events or otherwise.*

---